Company research

CBUS · NASDAQ

Cibus Inc

Healthcare · Biotechnology

$1.35

-4.26%

Close on Oct 29, 2026

Research data through 2026-10-29

Long-term research evidence only. No price targets, no trading signals, no recommendations.

Free research · no account required

Pro Investor Academy research

Research data through Oct 29, 2026. Research is updated periodically, not in real time.

Quality

22

of 100 · stored research reading

Stored Quality research reads 22 of 100, in the weaker band of the covered universe. This is a research reading about business durability, not a view on the share price.

Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.

How this is measured

Fundamental Momentum

—

Not currently available

Not currently available. Pro Investor Academy holds no current Fundamental Momentum measurement for this company.

Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.

How this is measured

Capital Returns

Weak

5

of 100 · stored research reading

Stored Capital Returns research reads 5 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 152.8% a year in the stored window.

Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.

How this is measured

Investor intelligence

What Investor adds for CBUS

The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.

Investor

See how this company ranks.

Unlock its Pro Investor Score and ranking across the research universe.

7 days · No credit card required

Investor

Understand the risk before you invest.

Unlock Risk Intelligence, Price Risk, and Market Confirmation.

7 days · No credit card required

Investor

Know why, not just what.

Unlock the Pro Research Brief with What Changed & Why, research history and tensions.

7 days · No credit card required

Investor

See what professional investors are reporting.

Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.

7 days · No credit card required

Investor

Ask the research.

Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.

7 days · No credit card required

Investor

Keep researching after today.

Save companies and monitor how their research changes over time.

7 days · No credit card required

Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.

Want to know what qualified today?

Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.

Research Collections

This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.

Browse collections

Learn the metrics on this page

Plain-English definitions, with the formula and the limitations of each measure.

In the company’s own words

What this company does

Cibus is a leading agricultural biotechnology company that primarily uses proprietary gene editing technologies to develop plant traits, which are specific genetic characteristics in the DNA of a plant’s seed. Plant traits, or characteristics, influence how a resulting plant functions and/or interacts with its environment. Cibus produces these edited plant traits by a unique process that is endeavoring to change the scale and speed of plant breeding for many major agricultural crops. Over the course of its history, Cibus has developed a proprietary time bound and predictable gene editing platform referred to as the Rapid Trait Development System ( RTDS ). This system allows Cibus to edit gene targets that are the basis of novel traits that can be integrated into Cibus’ customers’ best or elite seed genetics in as

little as one year. Cibus’ primary trait business opportunities continue to broaden as key jurisdictions around the world more closely align gene editing regulatory policies with those already in place for conventional breeding.

Cibus’ business operates within the global seed market, where management estimates that aggregate trait value across both genetically modified organism (GMO) and non-GMO seeds globally represents approximately $12.0 billion.

Cibus’ primary business is focused on the development of plant traits for some of the world’s major agricultural crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. These plant traits can be licensed to seed companies for inclusion in their seed products for a royalty. This is not a new business model as many companies have developed traits that have been added to seed products and have garnered significant royalties for their developers over many years. Importantly, farmers are well acquainted with the value of these seeds with traits. Cibus’ initial focus is on productivity traits, which can be associated with improving crop yields in the face of challenges such as weeds, pests, and diseases, can address environmental challenges with an overall reduction in the use of chemicals like fungicides, insecticides, or fertilizers, or can make crops more adaptable to environmental factors such as heat and drought in the face of climate change. In the near term, Cibus’ priority pipeline program centers on Rice herbicide tolerance (HT) traits. The Company believes its multiple, or in some cases stacked, Rice HT traits have estimated Potential Annual Addressable Royalties (as defined below) of over $200.0 million upon full commercialization across the Company’s initial target markets of Latin America and the United States.

Quoted from the business section of this company’s 10-K filed March 17, 2026. Read the filing

General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.